LET'S GET CLEAR ABOUT OCREVUS®
Pim, UK
Living with MS since 2021
On Ocrevus since 2021
Welcome to Roche MS, your Ocrevus support hub. It’s not always easy to get the answers you need about treatment for multiple sclerosis (MS), so this site is here to provide practical support and helpful information as you undergo treatment with Ocrevus.
LET'S GET CLEAR ABOUT OCREVUS®
Pim, UK
Living with MS since 2021
On Ocrevus since 2021
Welcome to Roche MS, your Ocrevus support hub. It’s not always easy to get the answers you need about treatment for multiple sclerosis (MS), so this site is here to provide practical support and helpful information as you undergo treatment with Ocrevus.
Just click on the type of MS you have to find the information you need
With relapsing remitting MS (RRMS) you will usually have repeated episodes of symptoms, but your symptoms disappear or improve between these relapses.
With primary progressive MS (PPMS), you will usually experience few or no relapses and instead, your symptoms will steadily increase as your disease progresses. There may be long periods where your symptoms seem to be stable.
This website aims to help you:
Find clear information about your treatment
Get expert answers to common questions, and details of some great resources for support and information
Discover insights from other people on Ocrevus
Learn what to expect and how to look after yourself on treatment days and afterwards
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Please report suspected side effects to the MHRA through the Yellow Card scheme, via the Yellow card website www.mhra.gov.uk/yellowcard, or the free Yellow Card app available in the Apple App Store or Google Play Store. You should also report side effects to Roche Products Ltd. by emailing the Roche Drug Safety Centre at welwyn.uk_dsc@roche.com or calling +44 (0) 1707 367554. By reporting side effects you can help provide more information on the safety of this medicine.
